Featuring an interview with Prof Karim Fizazi, including the following topics:

• Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
• Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
• Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
• Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
• Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
• Role of intermittent therapy in the treatment of prostate cancer (38:48)
• Treatment intensification approaches in prostate cancer (41:38)
• Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Featuring an interview with Dr Neeraj Agarwal, including the following topics:

• Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)
• Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)
• Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)
• Managing treatment-related adverse events from capivasertib (20:08)
• Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)
• Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

• Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)
• Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)
• Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)
• Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)

CME information and select publications